Amelioration of acute myocardial infarction injury through targeted ferritin nanocages loaded with an ALKBH5 inhibitor
- PMID: 34879293
- DOI: 10.1016/j.actbio.2021.11.041
Amelioration of acute myocardial infarction injury through targeted ferritin nanocages loaded with an ALKBH5 inhibitor
Abstract
The roles of m6A RNA methylation and mitochondrial metabolism in acute myocardial infarction (AMI) remain unclear. In this study, we demonstrated that m6A RNA methylation affected ischemia/reperfusion (I/R) injury in AMI through the "Erasers" protein ALKBH5-related metabolic reprogramming, characterized by the inhibition of enzyme activities of the tricarboxylic acid cycle; moreover, a surface-modified bioengineered ferritin nanocage was obtained from Archaeoglobus fulgidus, with a chimeric structure containing 8 lysine residues, SpyTag/SpyCatcher, and the C1q ligand Scarf1, which could disassemble and self-assemble in neutral solutions according to different Mg2+ concentrations. The surface-modified bioengineered ferritin nanocage targeted the dying cells in the infarct area under the guidance of Scarf1. These cells were then phagocytosed through recognition of their TfR1 receptor. Lysosomal escape was achieved through the 8 lysine residues on the nanocage, and the nanocage disassembled based on the differences in intracellular and extracellular Mg2+ concentrations. Finally, the ALKBH5 inhibitor IOX1 was loaded onto the ferritin nanocage and used in the AMI model, and it was found to effectively improve cardiac function. These results provide a potential strategy for the treatment of AMI in the future. STATEMENT OF SIGNIFICANCE: In acute myocardial infarction (AMI) induced by ischemia/reperfusion injury, m6A RNA methylation aggravates the injury through the "Erasers" protein ALKBH5-related metabolic reprogramming. To achieve precise treatment, genetic engineering-based recombinant expression technology was used to obtain a ferritin from Archaeoglobus fulgidus. The obtained ferritin was designated as HAfFtO, and it can disassemble and self-assemble in a neutral solution under different Mg2+ concentrations and achieve lysosomal escape. Three G4S linkers were used to connect SpyTag with HAfFtO to synthesize HAfFtO-ST and recombination Scarf1 containing SpyCatcher structure, namely SC-Sf. According to the SpyTag/SpyCatcher technique, HAfFtO-ST and SC-Sf can form a gentle and firm combination, namely HSSS. The ALKBH5 inhibitor IOX1 was loaded on HSSS to form HSSS-I. HSSS-I effectively improved the cardiac function and decreased the infarct size in AMI.
Keywords: ALKBH5; Ferritin; Methylation; Myocardial infarction.
Copyright © 2021 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors confirm that there are no conflicts of interest.
Similar articles
-
Alkylation Repair Homolog 5 Regulates N(6)-methyladenosine (m6A) Methylation of Mitsugumin 53 to Attenuate Myocardial Infarction by Inhibiting Apoptosis and Oxidative Stress.J Cardiovasc Pharmacol. 2024 Feb 1;83(2):183-192. doi: 10.1097/FJC.0000000000001515. J Cardiovasc Pharmacol. 2024. PMID: 37989146
-
METTL3 and ALKBH5 oppositely regulate m6A modification of TFEB mRNA, which dictates the fate of hypoxia/reoxygenation-treated cardiomyocytes.Autophagy. 2019 Aug;15(8):1419-1437. doi: 10.1080/15548627.2019.1586246. Epub 2019 Mar 17. Autophagy. 2019. PMID: 30870073 Free PMC article.
-
ALKBH5 regulates cardiomyocyte proliferation and heart regeneration by demethylating the mRNA of YTHDF1.Theranostics. 2021 Jan 1;11(6):3000-3016. doi: 10.7150/thno.47354. eCollection 2021. Theranostics. 2021. PMID: 33456585 Free PMC article.
-
RNA demethylase ALKBH5 in cancer: from mechanisms to therapeutic potential.J Hematol Oncol. 2022 Jan 21;15(1):8. doi: 10.1186/s13045-022-01224-4. J Hematol Oncol. 2022. PMID: 35063010 Free PMC article. Review.
-
Ferritin: A Multifunctional Nanoplatform for Biological Detection, Imaging Diagnosis, and Drug Delivery.Acc Chem Res. 2021 Sep 7;54(17):3313-3325. doi: 10.1021/acs.accounts.1c00267. Epub 2021 Aug 20. Acc Chem Res. 2021. PMID: 34415728 Review.
Cited by
-
N6-methyladenosine modification in ischemic stroke: Functions, regulation, and therapeutic potential.Heliyon. 2024 Jan 23;10(3):e25192. doi: 10.1016/j.heliyon.2024.e25192. eCollection 2024 Feb 15. Heliyon. 2024. PMID: 38317953 Free PMC article. Review.
-
Key m6A regulators mediated methylation modification pattern and immune infiltration characterization in hepatic ischemia-reperfusion injury.BMC Med Genomics. 2023 Dec 4;16(1):314. doi: 10.1186/s12920-023-01751-0. BMC Med Genomics. 2023. PMID: 38049811 Free PMC article.
-
RNA modification in cardiovascular disease: implications for therapeutic interventions.Signal Transduct Target Ther. 2023 Oct 27;8(1):412. doi: 10.1038/s41392-023-01638-7. Signal Transduct Target Ther. 2023. PMID: 37884527 Free PMC article. Review.
-
Ferritin-based nanomedicine for disease treatment.Med Rev (2021). 2023 Mar 10;3(1):49-74. doi: 10.1515/mr-2023-0001. eCollection 2023 Feb. Med Rev (2021). 2023. PMID: 37724111 Free PMC article. Review.
-
Critical roles of m6A methylation in cardiovascular diseases.Front Cardiovasc Med. 2023 May 19;10:1187514. doi: 10.3389/fcvm.2023.1187514. eCollection 2023. Front Cardiovasc Med. 2023. PMID: 37273867 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
